Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients.

Richard W Joseph, Jr., MD, Krishna V. Komanduri, M.D., R. M Saliba, MD, Amin Alousi, MD, S. Giralt, Gabriela Rondon, Joyce Neumann, Cindy Trevino, APN, Daniel R. Couriel, MD, Richard Champlin, U. Popat

Blood (2008) 112 (11): 2138.

https://doi.org/10.1182/blood.V112.11.2138.2138

Published: 2008

Journal Articles

Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation.

Blood (2007) 110 (11): 40.

https://doi.org/10.1182/blood.V110.11.40.40

Published: 2007

Journal Articles

A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS.

Marcos de Lima, L. Padua, S. Giralt, C. Hosing, K. Komanduri, M. Qazilbash, E.J. Shpall, P. Thall, S. Qureshi, G. McCormick, W. Tong, U. Popat, A. Soriano, R. Champlin, G. Garcia-Manero

Blood (2007) 110 (11): 3012.

https://doi.org/10.1182/blood.V110.11.3012.3012

Published: 2007

Journal Articles

Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).

Blood (2007) 110 (11): 2014.

https://doi.org/10.1182/blood.V110.11.2014.2014

Published: 2007

Journal Articles

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Marcos De Lima, X. Wang, P.F. Thall, D. Couriel, R.B. Jones, E.J. Shpall, U. Popat, S. Giralt, M. Korbling, R. Champlin, B.S. Andersson

Blood (2006) 108 (11): 322.

https://doi.org/10.1182/blood.V108.11.322.322

Published: 2006

Journal Articles

Influence of Allele Level HLA Typing on Unrelated Donor (UD) Transplantation for High Risk Myeloid Leukemias.

S. Parmar, M. Fernandez-Vina, P. Liu, P. Cano, B. S. Andersson, M. Munsell, S. Giralt, J. McMannis, E. J. Shpall, D. Couriel, S. Ghosh, R. Champlin, M. de Lima

Blood (2005) 106 (11): 2916.

https://doi.org/10.1182/blood.V106.11.2916.2916

Published: 2005

Journal Articles

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

B. Oran, R. Saliba, S. Giralt, D. Couriel, A. Carrasco-Yalan, C. Hosing, M. Shahjahan, E. de Meis, A. Anagnostopoulos, P. Anderlini, S. Ghosh, I. Khouri, R. Champlin, M. de Lima

Blood (2005) 106 (11): 838.

https://doi.org/10.1182/blood.V106.11.838.838

Published: 2005

Journal Articles

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Marcos de Lima, S. Giralt, Z. Caldera, G. McCormick, M. Qazilbash, P. Anderlini, E. J. Shpall, C. Hosing, M. Donato, S. Kornblau, I. Khouri, T. Martin, D. Couriel, R. Champlin

Blood (2005) 106 (11): 841.

https://doi.org/10.1182/blood.V106.11.841.841

Published: 2005

Journal Articles

Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.

M. de Lima, P. Thall, M. Shahjahan, W. Xuemei, D. Couriel, P. Anderlini, C. Hosing, M. Qazilbash, G. McCormick, C. Ippoliti, M. Donato, T. Martin, L. Metoyer, L. Griffin, P. Kebriaei, R. Champlin, S. Giralt

Blood (2004) 104 (11): 1824.

https://doi.org/10.1182/blood.V104.11.1824.1824

Published: 2004

Journal Articles

Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.

M. de Lima, D. Couriel, M. Munsell, M. Westmoreland, H. Shah, J. deJesus, C. Hosing, S. Ghosh, P. Anderlini, J. Gajewski, B. Andersson, S. Kornblau, B. Hocking, C. Ippoliti, S. Giralt, E. Shpall, R. Champlin

Blood (2004) 104 (11): 727.

https://doi.org/10.1182/blood.V104.11.727.727

Published: 2004

Journal Articles

Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator.

E. Shpall, M. de Lima, K. Chan, R. Champlin, A. Gee, P. Thall, K. Komanduri, D. Couriel, B. Andersson, C. Hosing, S. Giralt, S. Safa Karandish, T. Tara Sadeghi, B. Muriera, T. Peled, F. Grynspan, A. Nagler, J. McMannis

Blood (2004) 104 (11): 982.

https://doi.org/10.1182/blood.V104.11.982.982

Published: 2004

Journal Articles

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Blood (2004) 104 (11): 350.

https://doi.org/10.1182/blood.V104.11.350.350

Published: 2004

Journal Articles

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

D. Przepiorka, N. A. Kernan, C. Ippoliti, E. B. Papadopoulos, S. Giralt, I. Khouri, J.-G. Lu, J. Gajewski, A. Durett, K. Cleary, R. Champlin, B. S. Andersson, S. Light

Blood (2000) 95 (1): 83–89.

https://doi.org/10.1182/blood.V95.1.83

Published: 2000

Journal Articles

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

D Przepiorka, C Ippoliti, I Khouri, M Woo, R Mehra, D Le Bherz, S Giralt, J Gajewski, H Fischer, H Fritsche, AB Deisseroth, K Cleary, R Champlin, K Besien, B Andersson, R Maher, W Fitzsimmons

Blood (1996) 88 (11): 4383–4389.

https://doi.org/10.1182/blood.V88.11.4383.4383

Published: 1996

Journal Articles

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

S Giralt, J Hester, Y Huh, C Hirsch-Ginsberg, G Rondon, D Seong, M Lee, J Gajewski, K Van Besien, I Khouri

Blood (1995) 86 (11): 4337–4343.

https://doi.org/10.1182/blood.V86.11.4337.bloodjournal86114337

Published: 1995

Journal Articles

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional- dose chemotherapy before collection of autologous cells

M Talpaz, H Kantarjian, J Liang, L Calvert, J Hamer, P Tibbits, A Durett, D Claxton, S Giralt, I Khouri

Blood (1995) 85 (11): 3257–3263.

https://doi.org/10.1182/blood.V85.11.3257.bloodjournal85113257

Published: 1995

Journal Articles

Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]

M Korbling, D Przepiorka, YO Huh, H Engel, K van Besien, S Giralt, B Andersson, HD Kleine, D Seong, AB Deisseroth

Blood (1995) 85 (6): 1659–1665.

https://doi.org/10.1182/blood.V85.6.1659.bloodjournal8561659

Published: 1995

Journal Articles

Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma

MA Dimopoulos, R Alexanian, D Przepiorka, J Hester, B Andersson, S Giralt, R Mehra, K van Besien, KB Delasalle, C Reading

Blood (1993) 82 (8): 2324–2328.

https://doi.org/10.1182/blood.V82.8.2324.2324

Published: 1993

NARROW

High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients.

Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and “Mini”-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation.

A Dose and Schedule Finding Study of Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or MDS.

Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP).

Long-Term Follow-Up of IV Busulfan (Bu) with Fludarabine (Flu) vs IV Bu with Cyclophosphamide (Cy) as Pre (Allogeneic) Transplant Conditioning Therapy for AML/MDS.

Influence of Allele Level HLA Typing on Unrelated Donor (UD) Transplantation for High Risk Myeloid Leukemias.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS.

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

Phase I/II Study of Gemtuzumab Ozogamicin (GO), Fludarabine and Melphalan (FM) Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in AML/MDS.

Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.

Transplantation of Cord Blood Expanded Ex Vivo with Copper Chelator.

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

Tacrolimus and minidose methotrexate for prevention of acute graft- versus-host disease after matched unrelated donor marrow transplantation

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional- dose chemotherapy before collection of autologous cells

Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]

Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only